A Phase II Study of Vorinostat in Patients with Polycythaemia Vera and Essential Thrombocythaemia.
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2017
At a glance
- Drugs Vorinostat (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Therapeutic Use
- 25 Jun 2017 Results (n=40) investigating association of methylation age with respect to therapeutic response,presented at the 22nd Congress of the European Haematology Association.
- 10 Jun 2017 Biomarkers information updated
- 09 Dec 2011 Planned end date changed from 1 May 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History